Zydus Lifesciences Limited recently announced achieving positive proof of concept in a Phase II clinical study of its NLRP3 inflammasome inhibitor ZYIL1 to treat cryopyrin-associated periodic syndromes (CAPS), a rare, hereditary, life-long spectrum of auto-inflammatory conditions.
Does Zydus’ Promising CAPS Candidate Have An Edge Over Novartis’ Ilaris?
Potential In Chronic Inflammatory Diseases
Zydus has established proof of concept for ZYIL1, a NLRP3 inflammasome inhibitor to treat cryopyrin-associated periodic syndromes, via Phase II trials in Australia. Will the oral drug have an upper hand over injectables like Novartis’ Ilaris?
More from R&D
• By
Chinese biopharma companies’ alliance strategies are transitioning from immediate cash needs to more strategic management of portfolios, as MNCs continue to hunt for derisked assets.
• By
Faced with Trump’s hostile tariff moves, the UK aims to speed up clinical trial start times to support its pharma sector and invest £600m in a new health data research service.
• By
The biotech has rejected a takeover bid from Nordic Capital but a sale to private equity could be a solution to the public market's continued reluctance to adequately value PureTech’s hub-and-spoke business model.
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.
More from Scrip
• By
The US president's most recent comments suggest tariffs on pharma are imminent and Ireland has the most to lose.
• By
Chinese biopharma companies’ alliance strategies are transitioning from immediate cash needs to more strategic management of portfolios, as MNCs continue to hunt for derisked assets.
• By
The company announced positive Phase IIb data for Descartes-08 in myasthenia gravis, with especially strong efficacy among patients without prior biologic treatment.